Home › Astrocytoma › District of Columbia › Washington
Astrocytoma clinical trials in Washington, DC
6 studies for Astrocytoma are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Pediatric High-Grade Glioma Therapy
RecruitingObservational study
- Children's National Medical Center, Washington D.C.
Study of Olutasidenib and Temozolomide in HGG
RecruitingPhase 2
- Children's National Medical Center, Washington D.C.
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
RecruitingPhase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RecruitingEarly phase 1Healthy volunteers welcome
- Children's National Medical Center, Washington D.C.
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RecruitingPhase 2
- Children's National Medical Center, Washington D.C.
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
RecruitingPhase 1
- National Institutes of Health, Bethesda · 7 mi away
Astrocytoma trials in other cities
- Houston, TX14 studies
- Boston, MA13 studies
- New York City, NY9 studies
- Chicago, IL9 studies
- Miami, FL7 studies
- Philadelphia, PA7 studies
- Columbus, OH6 studies
- San Francisco, CA6 studies
- Durham, NC6 studies
- Seattle, WA6 studies
- Salt Lake City, UT5 studies
- Aurora, CO5 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.